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Abstract
Using a unique vaccine antigen matched and single HIV Clade C approach we have assessed the immunogenicity of a DNA-
poxvirus-protein strategy in mice and rabbits, administering MVA and protein immunizations either sequentially or
simultaneously and in the presence of a novel TLR4 adjuvant, GLA-AF. Mice were vaccinated with combinations of HIV env/
gag-pol-nef plasmid DNA followed by MVA-C (HIV env/gag-pol-nef) with HIV CN54gp140 protein (+/2GLA-AF adjuvant) and
either co-administered in different muscles of the same animal with MVA-C or given sequentially at 3-week intervals. The
DNA prime established a population of B cells that were able to mount a statistically significant anamnestic response to the
boost vaccines. The greatest antigen-specific antibody response was observed in animals that received all vaccine
components. Moreover, a high proportion of the total mucosal IgG (20 – 50%) present in the vaginal vault of these
vaccinated animals was vaccine antigen-specific. The potent elicitation of antigen-specific immune responses to this vaccine
modality was also confirmed in rabbits. Importantly, co-administration of MVA-C with the GLA-AF adjuvanted HIV
CN54gp140 protein significantly augmented the antigen-specific T cell responses to the Gag antigen, a transgene product
expressed by the MVA-C vector in a separate quadriceps muscle. We have demonstrated that co-administration of MVA and
GLA-AF adjuvanted HIV CN54gp140 protein was equally effective in the generation of humoral responses as a sequential
vaccination modality thus shortening and simplifying the immunization schedule. In addition, a significant further benefit of
the condensed vaccination regime was that T cell responses to proteins expressed by the MVA-C were potently enhanced,
an effect that was likely due to enhanced immunostimulation in the presence of systemic GLA-AF.
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Introduction
Designing an immunization strategy to induce potent cellular
immunity together with systemic and mucosal humoral responses
may prove critical in the development of an effective vaccine
against HIV-1 infection. Interest in multi-component or heterol-
ogous vaccine regimes has increased in recent years. This is due in
part to the RV144 Thai clinical trial of a prime/boost regime
using recombinant canary poxvirus (ALVAC-HIV) and two gp120
proteins (AIDSVAX B and E), that demonstrated modest vaccine
efficacy (31%) against HIV-1 acquisition, and is further supported
by a larger body of evidence from non-human primate studies that
demonstrate significant immunological benefit of multi-compo-
nent vaccination strategies [1–4]. Heterologous vaccination is
based on two core concepts. First, that the use of different vaccine
modalities (plasmids, viral vectors, and/or proteins) reduces the
potential elicitation of anti-vector immunity that would diminish
the potency and hence immunity-boosting potential of repeat
vaccinations [5,6]. Second, that the use of different vaccine
components and/or their order of administration can be used to
tailor resulting immunity, both quantitatively and qualitatively
[7,8]. Although there is clear evidence to support the former
concept [9,10], our understanding of how to tailor vaccine-elicited
immunity through the heterologous use of different vaccine
components is still very much in its infancy [11–15].
In this context, plasmid DNA is known to effectively prime CD4
helper, CD8 cytotoxic T cells and humoral immune responses,
readily detectable after recombinant vector or protein boost
vaccinations [16,17]. In contrast, poxviral vectors such as MVA,
although relatively poor at priming adaptive immunity, have been
successfully used to boost and expand pre-existing CD4 and CD8
cellular immunity [18,19]. Recombinant protein on the other
hand, is thought to be optimal for stimulating potent antigen-
specific B cell responses, particularly when administered with an
adjuvant [16,20]. Previous studies by us and others have
demonstrated potent enhancement of both cellular and humoral
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immune responses using TLR4 agonist adjuvants [21–23]. While
each of these individual components have the ability to elicit
immune responses, none are thought to be sufficient by themselves
to generate effective levels of both cellular and humoral immunity.
An additional consideration for the heterologous use of different
vaccine components is to increase the breadth of induced immune
responses. In this respect, responses focused too narrowly on a few
highly immunodominant epitopes can lead rapidly to immune
escape, particularly in the case of HIV-1 with its very high capacity
for mutation [24,25]. Furthermore, the broad genetic diversity of
HIV-1 even within individual clades provides a significant
challenge for immunogen design where induced neutralizing
antibody responses to individual recombinant proteins are often
isolate specific [26]. Plasmid DNA is thought to effectively prime
broad cellular responses [27,28] that can be effectively boosted by
viral vectors including MVA. Moreover, humoral responses to
recombinant proteins, primed by DNA and/or viral vectors are
larger and more diverse with respect to breadth of neutralization
than those elicited by protein alone [29–31]. Such differences in
terms of magnitude and breadth can be further influenced by the
provision of additional immunostimulation through the incorpo-
ration of adjuvant moieties [32–36].
In this study we assess the immunogenicity in mice of plasmid
DNA, MVA poxvirus and recombinant protein vaccine combi-
nations using matched HIV-1 Clade C Env gp140 and Gag-Pol-
Nef fusion antigens to determine the optimal vaccine regimen for
testing in a human clinical trial. We used an aqueous glucopyr-
anosyl lipid A (GLA-AF) adjuvant formulation to augment the
HIV CN54gp140 protein component of our vaccine. We
determined the relative immunogenicity of the individual vaccine
components when administered sequentially. Here animals were
primed using plasmid DNA to enhance immune breadth prior to
booster vaccinations with MVA and recombinant protein.
However, although sequential use of the individual components
offered potential for enhanced immune responsiveness, it also
significantly extended the duration of the vaccination regime,
potentially impacting on the feasibility of its implementation in
future human clinical trials. Therefore we also looked for evidence
for cross-talk between the different vaccine components and
assessed the potential positive or negative consequences of
shortening the vaccine regimen by co-administration rather than
sequential application of the MVA-C, CN54gp140 protein with or
without GLA-AF adjuvant.
Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Review Board
of Imperial College and work was performed in compliance with
project and personal animal experimentation licences granted by
the UK government in accordance with the Animals in Scientific
Procedures Act (1986).
Recombinant trimeric HIV-1 gp140, plasmid and viral
vectors, GLA-AF
A clade C HIV-1 envelope clone, designated p97CN54, was
obtained from an HIV infected Chinese patient [37,38], codon
optimized by GeneArt (Invitrogen, UK) was made available by
Prof H. Wolf and Prof R. Wagner (University of Regensburg,
Germany). Trimeric gp140 clade C envelope (gp120 plus the
external domain (ED) of gp41), designated CN54gp140, was
produced as a recombinant product in CHO cells (S. Jeffs -
personal communication), and the protein manufactured to GMP
specification by Polymun Scientific (Vienna, Austria). The identity
of the product was confirmed by mass spectrometric analysis of
tryptic fragments by the Medical Biomics Centre at St. George’s,
University of London. The trimeric product was stable, and has
been extensively tested to validate stability even when kept at room
temperature (D. Katinger - personal communication) and has
previously been reported to be immunogenic [39,40]. Two
plasmid DNA vectors were used in these studies. One contained
the CN54 Env transgene and the other a Gag-Pol-Nef genetic fusion
construct. Both plasmids utilized CMV enhancer/promoter with a
human T-cell leukemia type 1 regulatory element to drive
transgene expression [41]. The MVA pox vector was created by
Prof. Mariano Esteban (CSIC, Spain) and expresses the
CN54gp120 Env and the Gag-Pol-Nef polyprotein from two
back-to-back synthetic Early/Late transcriptional promoters
[42,43]. The micellar formulation of GLA has been denoted
previously as IDRI-AQ001 and is more generally denoted as
GLA-AF [44]. The biological and physicochemical characteriza-
tion of GLA has been published previously [45].
Mice, immunization and sampling
Female BALB/c mice (Harlan, UK), 6–8 weeks old, were
placed into groups (n = 10) and housed in a fully acclimatized
room. All animals were handled and procedures performed in
accordance with the UK Home Office Animals (Scientific
Procedures) Act 1986 in accordance with an internal ethics board
and a UK government approved project and personal licence
awarded to the corresponding author. Food and water were
supplied ad libitum. Mice were initially immunized at 3 week
intervals with three intramuscular 100 mg (50 mg each leg) plasmid
DNA vaccinations (two plasmids, one containing an HIV
CN54gp140 Env transgene injected into the left hind quadriceps
muscle in a volume of 50 ml and the other an HIV ZM96 Gag, Pol
and Nef fusion transgene injected into the right hind quadriceps
muscle also in a 50 ml volume, both constructs together being
termed DNA-C for clarity). This was followed by a 6 week rest
period where the animals did not receive any vaccinations. Mice
then received either two or four further vaccinations at 3 week
intervals with various combinations of IM delivered recombinant
poxvirus MVA env-gag-pol-nef (MVA-C) at 107 PFU in 50 ml and/
or recombinant gp140 with and without the TLR4 agonist GLA-
AF (IDRI, Seattle, USA). CN54gp140 was administered at 10 mg
per 50 ml dose and if GLA-AF was used it was co-administered
with the CN54gp140 protein at 20 mg per 50 ml dose. Tail bleeds
were collected before the start of the protocol and one day prior to
each vaccination without anti-coagulant and centrifuged in a
Heraeus Biofuge pico (Fisher, UK) at 1000 g for 10 min. The
serum was harvested and transferred into fresh 0.5 ml micro-
centrifuge tubes (Starlabs, UK), and stored at 220uC until
antigen-specific antibody concentrations were determined by
indirect quantitative ELISA. Vaginal lavage was carried out
immediately before the tail bleeds using three 25 ml washes/mouse
with sterile PBS that were subsequently pooled. Lavage samples
were incubated for 30 min with 4 ml of 256 stock solution
protease inhibitor (Roche Diagnostics, Germany) before centri-
fuging at 1000 g for 10 min. The fluid supernatant from these
treated samples was then transferred into a fresh 0.5 ml micro-
centrifuge tube, and stored at220uC until antigen-specific and the
total non-specific antibody concentrations were determined by
indirect quantitative ELISA.
Rabbits, immunization and sampling
Male and female New Zealand White rabbits (HsdIf:NZW;
Harlan, UK), 10–11 weeks old and with weights ranging from 2.0–
2.5 kg for males and 2.0–2.4 kg for females, were placed into
Immune Responses Elicited by DNA-MVA-gp140 Protein
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groups (n = 14; 7 males and 7 females per group) and housed in a
fully acclimatized room. All animals were handled and procedures
performed in accordance with the UK Home Office Animals
(Scientific Procedures) Act 1986 in accordance with an internal
ethics board and a UK government approved project and personal
licence awarded to the corresponding author. Food and water
were supplied ad libitum. Rabbits were immunized at 3 week
intervals with three intramuscular 8 mg (4 mg each leg) plasmid
DNA vaccinations (two plasmids, one containing an HIV
CN54gp140 Env transgene injected into the left hind quadriceps
muscle in a volume of 1 ml and the other an HIV ZM96 Gag, Pol
and Nef fusion transgene injected into the right hind quadriceps
muscle also in a 1 ml volume). This was followed by a 6 week rest
period where the animals did not receive any vaccinations. The
animals then received either two or four further vaccinations at 3
week intervals with various IM administered combinations of a
recombinant poxvirus (MVA env-gag-pol-nef (MVA-C) at
1.36108 PFU in 500 ml and/or recombinant gp140 with and
without the TLR4 agonist GLA-AF. CN54gp140 was adminis-
tered at 100 mg per 400 ml dose and if GLA-AF was used it was co-
administered with the CN54gp140 protein at 5 mg per 400 ml
dose. Ear bleeds (auricular artery) were collected before the start of
the protocol and one day prior to each vaccination without anti-
coagulant and centrifuged in a Heraeus Biofuge pico (Fisher, UK)
at 1000 g for 10 min. The serum was harvested and transferred
into fresh 0.5 ml micro-centrifuge tubes (Starlabs, UK), and stored
at 220uC until antigen-specific antibody levels were determined
by indirect quantitative ELISA. Vaginal vestibular sampling was
carried out at autopsy of the female animals. Briefly, two Weck-
Cel (Medtronic, UK) spears were used per female rabbit, one
being placed on the mucosal surface of the vaginal and another on
the mucosal surface of the vestibule for 2 min to soak up any
secretion present. The spears were then removed and placed into
the top chamber of a Spin-X tube that contained 300 ml of a high
salt extraction buffer (100 ml PBS, 1.5 g NaCl, 1 ml 1006
Protease Inhibitors, 20 ul 10% NaN3). Each spear head was cut
from the stalk and the handle discarded and the tubes were then
frozen at #55uC until required for further processing which
consisted of centrifugation of the thawed tube for 30 min at
14,000 rpm through the Spin-X filter and then immediate analysis
of the mucosally sourced sample by indirect quantitative ELISA.
Anti-CN54gp140 antibody quantitative ELISA
Serum and mucosal antigen-specific gp140 binding antibodies
against recombinant CN54gp140 were measured using a stan-
dardized ELISA. Maxisorp high binding 96-well plates were
coated with 100 ml recombinant CN54 gp140 at 5 mg/ml in PBS
for overnight at 4uC. The standard immunoglobulins were
captured with a combination of anti-murine lambda and kappa
light chain specific antibodies (Serotec, UK). These capture
antibodies were coated onto the maxisorp plates overnight at 4uC
(100 ml of a 1:3200 dilution; Serotec). Coated plates were washed
three times in PBS-T before blocking with 200 ml PBS-T
containing 1% bovine serum albumin for 1 hour at 37uC. After
further washing, sera diluted 1/100 or mucosal wash samples
diluted 1/10 were added to the antigen coated wells and a
standard titration of immunoglobulin standards added to the
kappa/lambda capture antibody coated wells at 50 ml/well and
incubated for 1 hour at 37uC. Plates were washed four times
before the addition of 100 ml of a 1/4,000 dilution of goat anti-
mouse Ig-HRP (various isotypes - matched to the standard
immunoglobulin isotype; Southern Biotech) secondary antibody
and incubated for 1 hour at 37uC. The plates were washed four
times and developed with 50 ml/well of KPL SureBlue TMB
substrate (Insight Biotechnology, UK). The IgA isotype, that was
biotin labeled, required a further Streptavidin-HRP (R&D
systems) amplification step prior to TMB development. The
reaction was stopped after 15 min by adding 50 ml/well 1 M
H2SO4, and the absorbance read at 450 nm on a KC4
spectrophotometer.
IFN-gamma T Cell ELISpot
Spleens were harvested from each animal and processed as
described previously [23]. Antigen-reactive splenocyte T cells were
enumerated using a standardized IFN-gamma T cell ELISpot
(Shattock lab SOP). Briefly, IFN-gamma capture antibody was
coated overnight on ethanol activated HTS multiscreen (Millipore)
plates at 4uC, then washed with sterile PBS. 50 ml of splenocytes
(56106 cells/ml) were added to each well together with various
Env or Gag peptide pools (15-mers overlapping by 11aa; each
peptide used at a final concentration of 5 mg/ml; Env Pool 1 = 78
peptides, Env Pool 2 = 78 peptides, Gag Pool 1 = 61 peptides, Gag
Pool 2 = 60 peptides) or positive and negative controls of ConA
(5 mg/ml) or medium alone respectively (50 ml) and incubated for
16–18 hours before further washing and development of the spots
using a streptavidin labelled IFN-gamma sandwich detection
antibody and streptavidin alkaline phosphatase. Colour was
developed with the BCIP/NBT substrate solution. ELISpot plates
were read using an AID ELISpot reader ELR03 (Autoimmun
Diagnostika GmbH, Ger). ELISpot well counts were defined as
positive if they were more than twice the standard deviation of the
background unstimulated cells and were above 50 spot forming
units (SFU) after subtraction of the background.
Intracellular Cytokine Staining and Analysis
Splenocytes were cultured at 37uC in a 5% CO2 environment
for 6 hours in the presence of RPMI medium alone (unstimulated
control) or Env and Gag peptide pools (specific responses – each
peptide present at a concentration of 5 mg/ml with pools being the
same as described for the ELISpot assays and total DMSO
concentration was less than 2% in all final peptide pool
stimulations) or 100 ng of phorbol myristate acetate (PMA) per
ml plus 1 mg of ionomycin per ml (positive control). All cultures
contained brefeldin A (GolgiPlug; BD Pharmingen) at 10 mg/ml to
disrupt Golgi apparatus transport, thereby causing intracellular
cytokine accumulation and the co-stimulatory antibodies anti-
mouse CD28 and CD49d and were in a total volume of 100 ml.
The cultured stimulated cells were washed then stained with live/
dead fixable violet (Invitrogen, UK), washed again in PBS-2%
FCS then incubated with mAbs specific for cell surface molecules
(CD3-V500, clone 500A2; CD4-APC-Cy7, clone GK1.5 and
CD8-PerCp Cy5.5, clone 53–6.7; all BD Biosciences, UK) prior to
permeabilization and fixation where briefly, the cells were washed
once with PBS-2% FCS and then permeabilized with Cell Fix/
Perm solution (BD Pharmingen) in accordance with the permea-
bilization protocol. Cells were washed twice with 2.5 volumes of
16 Perm/Wash buffer and then stained with 1 mg of each
anticytokine mAb per 106 cells (IFNc-Pe-Cy7, clone XMG1.2;
TNFa-FITC, clone MP6-XT22 and IL-2-PE, clone JES6-5H4; all
BD Biosciences, UK). Anticytokine mAb titers for optimal staining
were determined in preliminary experiments. Cells were washed
twice with 2 ml of 16Perm/Wash buffer and once with PBS and
then fixed in 1.5% formaldehyde-PBS. Samples were analyzed on
a FACS CantoII instrument with FACS Diva software. Total
single cell lymphocytes were gated using forward and side scatter
and a ‘singlets’ gate prior to identification of any dead cells that
had taken up the live/dead stain and 46104 gated and live CD3
positive T cells were collected. Positive cytokine responses were
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determined by using fluorescence minus one (FMO) to assess non-
specific antibody staining and the use of an unstimulated control
for each individual splenocyte sample to determine any back-
ground activation status giving a positive cytokine response. Gates
were set using the FMO as the absolute guide and any background
cytokine response in the unstimulated cells were subtracted from
the specific peptide pool generated response. Data analysis was
performed with FlowJo (Treestar Inc., OR, USA) and the analysis
and presentation of distributions was performed using SPICE
version 5.22, downloaded from http://exon.niaid.nih.gov [46].
Statistical Analysis
The mean serum and mucosal antibody levels were compared
using a Mann-Whitney non-parametric test. ELISpot SFU of each
group were analysed by one-way analysis of variance (ANOVA)
with a Fisher’s least significant difference multiple-comparison test.
A p value of ,0.05 was considered significant. The SPICE
software comparison of distributions was performed using a
student’s t test and a partial permutation test as described [46].
Results
Recombinant DNA, MVA and GLA adjuvanted protein
elicit substantial vaccine-antigen specific humoral
immune responses
Although DNA, MVA and recombinant protein immunogens
have been assessed when used sequentially we set out to determine
if there was similar or improved immunological outcome when
MVA and protein were used in combination to boost DNA
priming. In addition, we assessed the impact of GLA-AF, a potent
TLR4 agonist. DNA intramuscular vaccinations contained two
plasmid constructs (DNA-C), one expressing a codon optimized
gag-pol-nef transgene derived from the clade C p96ZM651.8
molecular clone and the other a codon optimized env transgene
from the C/B9 HIV-1 97CN54 isolate. The MVA vector
contained a 97CN54 gag-pol-nef fusion transgene and a
97CN54 env construct that coded for the gp120 version of Env
also from the C/B9 HIV-1 97CN54 isolate. Both transgenes were
codon optimized and expressed within one MVA-C construct
using back-to-back synthetic early promoters. Vectors were
injected into the quadricep muscles and mice where immunized
with individual or combined vaccine components as detailed in
Table 1.
Antigen-specific IgG and IgA levels in serum and mucosal
samples were determined by semi-quantitative ELISA and the
Th1/Th2 indicator isotypes IgG1 and IgG2a were also measured
in the serum. We first analysed the immunogenicity of the
recombinant MVA-C and the CN54gp140 protein in various
combinations with or without adjuvant in those animals that had
received plasmid DNA-C priming (Figure 1). While three DNA
vaccinations elicited low levels of CN54gp140 antigen-specific
serum IgG responses (30 mg/ml at 9 weeks) these were substan-
tially augmented after boosting with recombinant MVA-C vector
plus CN54gp140 protein with or without the GLA-AF adjuvant.
When compared to animals boosted with recombinant MVA-C
alone, the groups that received MVA-C plus recombinant protein
had significantly higher antigen-specific serum IgG (***p,0.0001,
Mann-Whitney) with the highest levels observed in the group that
received MVA-C with GLA-AF adjuvanted protein (mean
1969.7 ug/ml). Furthermore, the peak antigen-specific IgG
antibody responses achieved when adjuvanted CN54gp140
protein was administered without the MVA-C vector was also
significantly greater than MVA-C boosting alone (***p,0.0001,
Mann-Whitney), although lower but not significantly different
than animals that received both the MVA-C plus
CN54gp10+GLA-AF (DNA – MVA/gp140+GLA vs DNA –
gp140+GLA: p = 0.063, Mann-Whitney). Therefore, both groups
of animals that received recombinant CN54gp140+GLA-AF
exhibited the highest levels of serum antigen-specific IgG.
Interestingly, animals that received MVA/gp140+GLA inocula-
tions displayed significantly higher responses than those receiving
gp140+GLA alone despite the MVA-C alone appearing to be a
relatively poor booster of the DNA-C primed immune response.
This suggests that the MVA-C component, while not directly
augmenting antigen-specific antibody levels, does play a role in
enhancing the general immune activation, either by itself or in a
combination with the other boost vaccine components. These
significant differences observed at peak response three weeks after
the first boost inoculation were not maintained when a second
boost was given and the antigen-specific IgG serum antibody
reduced to similar levels in these three groups after a further three
weeks.
We then assessed the isotype profile of the peak serum and
mucosal CN54gp140 antigen-specific Ig responses elicited by each
vaccination regimen (week 15 after first plasmid DNA-C
inoculation; Figure 1). While serum IgG levels (including IgG,
IgG1 and IgG2a) were readily detected in all groups only very low
levels of specific IgA responses were observed in the serum
(Figure 1B). Furthermore, there were only very low levels of
vaccine antigen-specific IgA in mucosal wash samples (Figure 2A)
but moderate levels of IgG, with greater than 50% of the total
mucosally secreted IgG antibody being specific for CN54gp140 in
Table 1. Murine vaccination groups.
Week
0 3 6 9 12 15 18 21
A - DNA - MVA -gp140+GLA DNA DNA DNA - MVA MVA gp140+GLA gp140+GLA
B - DNA - MVA/gp140+GLA DNA DNA DNA - MVA/gp140+GLA MVA/gp140+GLA
C - DNA - gp140+GLA DNA DNA DNA - gp140+GLA gp140+GLA
D - DNA - MVA/gp140 DNA DNA DNA - MVA/gp140 MVA/gp140
E - MVA - gp140+GLA - - - - MVA MVA gp140+GLA gp140+GLA
F - MVA/gp140+GLA - - - - MVA/gp140+GLA MVA/gp140+GLA
G - DNA DNA DNA DNA - - -
Female BALB/c mice received immunizations at three week intervals either sequentially or in combination into different quadricep muscles.
doi:10.1371/journal.pone.0084707.t001
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some animals (range 0.3–86% depending on regimen). Interest-
ingly the highest level of mucosally sourced IgG was not detected
in the DNA – MVA/gp140+GLA group which had the highest
serum antigen-specific IgG response, but rather in the group that
had received adjuvanted protein only without MVA. To further
characterize the vaccine-elicited humoral response we assessed the
potential skewing of the immune response using the IgG2a:IgG1
ratio as a surrogate for Th1:Th2 bias (Figure 2B). We measured
the IgG1 and IgG2a immunoglobulin isotypes at week 12, when
the animals had received the three DNA-C priming vaccinations,
and then again at week 15, three weeks after they had been
boosted. Animals that were boosted with the MVA-C vector alone
showed no alteration to the bias of the immune response, however
all groups that received a recombinant protein boost demonstrated
some skewing towards Th2, a known consequence of DNA prime/
protein boosting in BALB/c mice [47]. However, the presence of
the TLR4 agonist GLA-AF prevented or reduced this strong bias
as previously described [48,49].
Anamnestic humoral responses to recombinant
CN54gp140 protein or MVA after plasmid DNA priming
We assessed the contribution of the plasmid DNA within our
vaccine regimen by comparing the vaccine-generated immune
responses of groups of animals that did not receive DNA-C
priming inoculations with those that received three DNA-C prime
vaccinations (Table 1). We first compared those animals that
received the MVA-C vector together with the adjuvanted
CN54gp140 protein and observed a clear anamnestic response
after the boost inoculation at week 12, demonstrating that the
DNA-C priming inoculation did indeed elicit a population of
antigen-responsive immune cells (Figure 3A). Those animals that
did not receive the plasmid DNA-C prime vaccination did not
respond until after the second administration of MVA/
gp140+GLA and even then the level of the peak response in this
cohort was less than 25% of the peak value measured in the DNA
primed animals.
We next looked at those groups of animals where the boost
inoculations were administered separately at three-week intervals
rather than given together. We noted that the MVA-C vector was
able to boost the antigen-specific immune response in DNA-C
experienced animals, though the second MVA-C inoculation
appeared to have a detrimental effect, possibly due to an
insufficient gap between the boost vaccinations and/or potential
response modulation by the many immune control factors
expressed by attenuated MVA [50] (Figure 3B). Interestingly,
the MVA-C was a poor primer of immunity and the group of
animals that had not received any DNA-C priming immunizations
(which were effectively naı¨ve) responded weakly to inoculation
with MVA-C vector alone, while a reasonable level of antigen-
specific immunity was achieved in this group after the second
adjuvanted protein inoculation. At the end of the series of
Figure 1. Gp140-Specific Serum IgG responses in mice primed with DNA. (A) Animals (n= 10) were inoculated 3 times with 100 mg plasmid
DNA (IM at week 0, 3 and 6) then boosted with variations of MVA-C (107 PFU) and/or recombinant protein with/without GLA-AF adjuvant (IM
inoculation at week 12 and 15). CN54gp140 recombinant protein (10 mg) and GLA-AF adjuvant (20 mg) were admixed and injected into one
quadricep muscle. If MVA-C was administered at the same time it was inoculated into the other quadricep muscle. Serum was taken one day prior to
each vaccination and the antigen-specific IgG antibody was assessed by an immunoglobulin ELISA with a murine purified IgG standard curve. (B)
Comparison of the serum IgG or IgA levels in each DNA primed group at peak response (Week 15). Antigen-specific IgG concentrations are shown in
mg/ml (+/2 SEM). Statistical comparisons were performed using a Mann-Whitney test (***p,0.0001, comparison to DNA – MVA-C group).
doi:10.1371/journal.pone.0084707.g001
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Figure 2. Gp140-Specific Mucosal IgG or IgA responses and serum IgG Th1/Th2 bias in DNA primed mice boosted with various
combinations of MVA-C and/or CN54gp140 and GLA-AF. Female BALB/c mice (n= 10) inoculated with a total of 100 ug plasmid DNA (50 ug
per leg; IM at week 0, 3 and 6) then boosted with variations of 107 PFU MVA-C and/or 10 mg recombinant protein with/without 20 mg GLA-AF
adjuvant (IM inoculation at week 12) were assessed at week 15, three weeks after the first boost event. (A) Mucosal vaginal wash samples contained
moderate levels of vaccine antigen-specific IgG but very low levels of specific IgA (***p,0.0001; **p= 0.0015). (B) The effect of the boost inoculation
upon the Th1:Th2 bias was assessed with the ratio of the IgG2a:IgG1 immunoglobulin isotype. Antigen-specific IgG, IgG1, IgG2a or IgA antibody was
assessed by an immunoglobulin ELISA with a murine purified IgG, IgG1, IgG2a or IgA standard curve. Antigen-specific Ig concentrations are shown in
mg/ml (+/2 SEM). Statistical comparisons were performed using a Mann-Whitney test.
doi:10.1371/journal.pone.0084707.g002
Figure 3. Anamnestic humoral responses after plasmid DNA vaccination. (A) Mice that had been previously inoculated three times with
plasmid DNA expressing the CN54gp140 Env transgene elicited a memory B cell population that differentiated into antigen-specific antibody
secreting cells after a single MVA/gp140+GLA vaccination. (B) MVA alone was also able to re-stimulate this memory population of B cells and this was
again further boosted by subsequent inoculations of the recombinant adjuvanted antigen CN54gp140. Antigen-specific IgG antibody was assessed
by an immunoglobulin ELISA and concentrations are shown in mg/ml (+/2 SEM).
doi:10.1371/journal.pone.0084707.g003
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vaccinations however, both regimens (+/2 DNA-C priming)
elicited similar levels of antigen-specific serum immunoglobulin.
T cell responses to vector-derived antigens were altered
in the presence of the GLA-AF adjuvant in mice
Subsequently we evaluated the cellular immune response in the
systemic compartment of these various vaccine regimen groups
(Table 1). An IFN-c ELISpot assay of splenocytes from each
animal demonstrated that both the DNA – MVA – gp140+GLA
and the DNA – MVA/gp140+GLA groups, where the recombi-
nant adjuvant was given sequentially or in a regime shortening
combination, developed CN54gp140 envelope-specific T cell
responses that were dramatically higher than the other vaccine
groups (Figure 4A) suggesting that the presence of all vaccine
components was required for optimal T cell immune responses.
The response to peptides contained within the Env1 pool
(****p,0.001; ANOVA) were significantly greater than the Env2
Pool suggesting the presence of one or more immunodominant T
cell epitopes within the first half of the CN54 envelope protein.
Splenocyte responses to peptides in the Env2 pool were also
significantly higher than those to the Gag peptide pools in the two
groups that had received all the vaccine components (*p,0.05;
ANOVA). Interestingly however, the only vaccination group to
demonstrate significantly higher Gag-specific T cell responses than
the DNA vaccine alone group was the regime shortening DNA –
MVA/gp140+GLA cohort where the GLA adjuvant was given
concurrently (though in a separate leg) with the MVA-C vector
(Gag 1 - **p,0.01; Gag 2 – ***p,0.005, ANOVA). The gag
antigen was only expressed in the DNA-C plasmid and the MVA-
C vector, strongly suggesting that the GLA-AF TLR4 adjuvant, in
addition to augmenting the humoral immune response to the
recombinant CN54gp140 protein was also able to act systemically
and enhance the cellular immune response to the MVA-C vector
expressed transgenes (Figure 4B).
We then used intracellular cytokine staining (ICS) to assess the
polyfunctionality or cytokine response profile of CD4 and CD8 T
cells from each vaccination group. From these analyses it was clear
that the CD4 splenocyte T cells displayed a greater degree of
polyfunctionality than CD8 T cells, with very low percentages of
CD8+ cells expressing all three cytokines, IFN-c, TNF-a and IL-2
(Figure 5 and Table S1). Animals primed with plasmid DNA-C
contained moderate populations of cells expressing all three
cytokines whereas those animals that did not receive DNA-C
priming exhibited no triple-expressors, strongly suggesting a role
for DNA-C priming in broadening the cellular immune response.
Of particular note was the observation that vaccination groups
that received all vaccine components demonstrated the greatest
diversity of cytokine expression and contained the largest
populations of double- and triple-cytokine expressing CD4 T
cells. Both the sequential DNA – MVA – gp140+GLA and the
regime shortened DNA – MVA/gp140+GLA groups contained
highly polyfunctional cytokine expressing populations that re-
sponded to the Env1, Env2 and the Gag2 peptide pools, suggesting
that these regimens were able to elicit a more divergent vaccine-
antigen specific population of T cells.
The vaccine components elicited high antigen-specific
serum IgG in rabbits
The sequential and shortened vaccine regimens were then
assessed in a second species to determine whether the very high
levels of serum antigen-specific antibody were attainable in
animals other than mice. We injected male and female rabbits
with 4 mg of each of the naked plasmid DNA-Cs (CN54 Env in the
left hind leg quadriceps and ZM96 Gag-pol-nef in the right hind
quadriceps) followed by 1.36108 PFU MVA-C either alone or
along with 100 mg CN54gp140+5 mg GLA-AF according to the
vaccination schedule in Table 2, as part of a toxicological and
immunogenicity analysis in preparation for translation into a
clinical trial. The CN54gp140-specific serum IgG responses
demonstrated that these vaccine regimens elicited comparably
high humoral responses to those seen in mice, with no statistically
significant difference between the sequential and the shortened
regimes (Figure 6A). Furthermore, and in broad accordance with
the initial murine studies, the level of mucosally sourced antigen-
specific IgG was 10–20% of the total immunoglobulin present in
the rabbit genital tract (Figure 6B). Mucosal IgA was analysed but
none was detected in vaginal samples from these animals (data not
shown).
Discussion
We set out to determine the relative immunogenicity of the
different components of a DNA-MVA-Protein (+/2 adjuvant)
vaccine regimen in order to design an optimal immunization
regime for a phase I human clinical trial. We wanted to assess
whether a regime shortening approach was equivalent or better
than sequential vaccinations in generating vaccine-antigen specific
immunity. We performed a number of regimen permutations,
each designed to investigate the contribution of individual
components of a heterologous vector but HIV Clade C antigen-
matched strategy, and assessed the vaccine-elicited responses in
both cellular and humoral compartments. Quantitatively, we
measured levels of serum and mucosal antibody and the degree of
T cell reactivity and qualitatively we assessed antibody isotype
skewing and the polyfunctionality of the antigen-specific cellular
response.
In agreement with previous publications, naked plasmid DNA-
C vaccinations elicited moderate levels of antigen-specific IgG
($30 ug/ml) [51]. In addition, DNA-C priming was able to
effectively generate and establish a population of memory B cells
that could be effectively expanded with either a recombinant
vector boost inoculation that expressed the protein from encoded
transgenes or administration of recombinant protein itself, an
effect that was confirmed in a subsequent rabbit immunogenicity
experiment. The boost components of the vaccine regimen were
also able to elicit antigen-specific humoral responses when given
without any DNA-C prime vaccination, though the MVA-C
vector generated low-level responses, likely consistent with a better
ability to promote cellular immunity. As we have previously
observed, intramuscular injection of recombinant proteins elicit
little antigen-specific IgA, with only very low levels detected in the
serum and none in mucosal secretions [52].
An analysis of splenic T cell responses demonstrated that the
DNA-C priming contributed very significantly to the overall
magnitude of the cellular immune response. Animals that had not
received any DNA-C prime inoculations had very low levels of T
cell reactivity, barely registering above background. In agreement
with published work performed in both mice and humans that
demonstrated dominant T cell responses to the V1/V2 segment
and the V3 loop of the HIV envelope protein we found high
splenocyte T cell reactivity to the Env 1 peptide set that spans
these regions of the CN54gp140 vaccine antigen [53–55]. We also
carried out an analysis of the polyfunctionality, or functional
diversity of the cellular immune response. Those animals that had
been primed with DNA-C all demonstrated a greater degree of
polyfunctional CD4 and CD8 T cell responses at the end of their
vaccination regimen. In contrast, the animals that received MVA-
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C and HIV CN54gp140 protein without DNA-C priming,
whether within a shortened or sequential regimen had T cells
that exhibited a limited ability to secrete more than one cytokine,
with a majority of the cells analysed being monocytokine
expressors. Conversely, the groups that had an additional
prior DNA-C priming vaccination contained majority popula-
tions of multicytokine expressors, particularly in the CD4 T cell
compartment.
Interestingly, administration of the GLA-AF adjuvant+
CN54gp140 at the same time as the MVA-C vector, although
injected into different hind leg quadricep muscles, was able to
significantly augment the immune response to transgene products
only expressed by the vector and not present in the GLA-AF co-
formulated recombinant protein. As the components were
administered into different legs of the animals this observation
strongly suggests that the GLA-AF has systemic adjuvant effects,
heightening the immune response to the transgenes expressed by
the MVA-C vector. An additional effect of the GLA-AF adjuvant
was a modification of the degree of Th1:Th2 skewing of the
humoral response. In groups that received DNA or DNA – MVA
inoculations we observed no bias in the immune response but
those groups that had received any recombinant protein vaccina-
tions as part of the regimen demonstrated clear skewing toward a
Th2 biased response. We were able to show with the addition of
the TLR4 agonist that this strong Th2 bias was prevented,
demonstrating the potential utility of GLA-AF to manipulate or
‘tailor’ immune responses.
Figure 4. Splenocyte IFN-c ELISpot responses to specific vaccine antigen derived peptide pools. Cells isolated from mouse spleens at
termination were stimulated with peptide pools (15 mers overlapping by 11 aa) that covered the entire coding sequence of the Gag and Env protein
(two pools for each peptide) that were expressed from the transgenes present in the two plasmid DNAs and the MVA-C vector. (A) Specific peptide
pool responses of splenocytes from all study groups. (B) Comparison of splenocyte IFN-c ELISpot responses to the Env and the Gag peptide pools in
animals that had been DNA primed then inoculated with either MVA-C and CN54gp140+GLA sequentially or with the MVA and protein or with all
three boost vaccine components concurrently. Responses from each group of animals are shown as group mean spot forming units (SFU)/million
splenocytes +/2 SEM. Groups were statistically compared using a one-way Anova (*p,0.05; **p,0.01; ***p,0.005; **** p,0.001).
doi:10.1371/journal.pone.0084707.g004
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Figure 5. Polyfunctional cytokine responses of peptide pool stimulated splenocytes. Cells from each animal were stimulated with each
different peptide pool for 6 hours at 37uC in the presence of a golgi secretion inhibitor. CD4+ or CD8+ T cell populations were gated and single,
double or triple cytokine expressing cell percentage enumerated. The percentage cytokine expression of each animal was averaged within the group
and is expressed as a pie-chart of relative proportions of the total cytokine expressing cell population. Pie slice colour key indicates the particular
cytokine(s) expressed.
doi:10.1371/journal.pone.0084707.g005
Figure 6. Vaccine elicited CN54gp140-specific serum and mucosal IgG responses in rabbits. Male and female NZW rabbits were primed
with three DNA inoculations (8 mg total; 4 mg each leg) into their quadricep muscles then boosted with either MVA – gp140+GLA given sequentially
or MVA/gp140+GLA administered concurrently in separate leg muscles (MVA-C at 1.36108 PFU in 500 ml; CN54gp140 at 100 mg in 400 ml; GLA-AF at
5 mg in 400 ml – co-formulated with CN54gp140 recombinant protein). The antigen-specific serum IgG response over the course of the vaccine
regimen (A) and the mucosal IgG response at termination (B). Antigen-specific rabbit IgG antibody was assessed by an immunoglobulin ELISA with a
rabbit purified IgG standard curve. Antigen-specific IgG concentrations are shown in mg/ml (+/2 SEM).
doi:10.1371/journal.pone.0084707.g006
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Taken together these results strongly indicate that the DNA-C
inoculations enhance the breadth of the immune response and also
that this diversity is not swamped by subsequent vaccination with
adjuvanted protein, as the T cell cytokine analysis was performed
at the end of the vaccination schedule. We have shown that these
vaccine components are immunogenic in both mice and rabbits
and are able to elicit high levels of humoral responses and large
numbers of systemic antigen-specific T cells, particularly to the
envelope protein. We have further demonstrated that the
concurrent administration of a vectored vaccine with a GLA-AF
adjuvanted recombinant protein has significant and unexpected
advantages, expanding responses to the vector expressed antigens
and promoting the elicitation of a polyfunctional cellular response.
Moreover, there are clear benefits of a shortened vaccine regimen
that is equivalent or immunologically preferential to a sequential
multi-visit dosing schedule, through increased compliance and
lower costs.
Supporting Information
Table S1 Percentage positive of gated and live CD4 and
CD8 T cells that secreted cytokine in response to peptide
pools Env 1, Env 2, Gag 1 or Gag 2.
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